Zoetis Inc. (ZTS): Price and Financial Metrics


Zoetis Inc. (ZTS)

Today's Latest Price: $162.81 USD

1.63 (1.01%)

Updated Oct 22 1:44pm

Add ZTS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ZTS Stock Summary

  • ZTS has a market capitalization of $76,583,823,391 -- more than approximately 97.51% of US stocks.
  • With a one year PEG ratio of 330.14, Zoetis Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 89.6% of US stocks.
  • Price to trailing twelve month operating cash flow for ZTS is currently 39.6, higher than 90.62% of US stocks with positive operating cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Zoetis Inc are BDX, SYK, SE, MELI, and CAT.
  • ZTS's SEC filings can be seen here. And to visit Zoetis Inc's official web site, go to www.zoetis.com.

ZTS Stock Price Chart Interactive Chart >

Price chart for ZTS

ZTS Price/Volume Stats

Current price $162.81 52-week high $168.96
Prev. close $161.18 52-week low $90.14
Day low $161.25 Volume 356,417
Day high $162.86 Avg. volume 2,092,028
50-day MA $160.80 Dividend yield 0.5%
200-day MA $140.82 Market Cap 77.36B

Zoetis Inc. (ZTS) Company Bio


Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.

ZTS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$162.81$72.81 -54%

Below please find a table outlining a discounted cash flow forecast for ZTS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Zoetis Inc ranked in the 29th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 54.17%. As for the metrics that stood out in our discounted cash flow analysis of Zoetis Inc, consider:

  • The company has produced more trailing twelve month cash flow than 82.9% of its sector Healthcare.
  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 22.09% of the free cash flow producing stocks we're observing.
  • ZTS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 37.17% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-55%
1%-55%
2%-54%
3%-54%
4%-54%
5%-53%

Want more companies with a valuation profile/forecast similar to that of Zoetis Inc? See HAPP, ILMN, CPIX, LMAT, and PKI.


ZTS Latest News Stream


Event/Time News Detail
Loading, please wait...

ZTS Latest Social Stream


Loading social stream, please wait...

View Full ZTS Social Stream

Latest ZTS News From Around the Web

Below are the latest news stories about Zoetis Inc that investors may wish to consider to help them evaluate ZTS as an investment opportunity.

The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Th...

Benzinga | October 1, 2020

Zoetis to Host Webcast and Conference Call on Third Quarter 2020 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to report third quarter 2020 financial results on Nov. 5.

Business Wire | September 30, 2020

Livestock Breeding Management Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026|Boehringer Ingelheim, Zoetis, Merck, Elanco, Bayer, Virbac

Los Angeles, United State, – – QY Research recently added a research report, Global Livestock Breeding Management Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Livestock Breeding Management market. It highlights

OpenPR | September 29, 2020

Livestock Pain Management Market Analysis, Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts 2026Boehringer Ingelheim, Zoetis, Merck, Elanco, Bayer, Virbac

Los Angeles, United State, – – QY Research recently added a research report, Global Livestock Pain Management Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Livestock Pain Management market. It highlights

OpenPR | September 29, 2020

Livestock Pain Relief and Prevention Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and Production ValueBoehringer Ingelheim, Zoetis, Merck, Elanco, Bayer, Virbac

Los Angeles, United State, – – QY Research recently added a research report, Global Livestock Pain Relief and Prevention Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Livestock Pain Relief and

OpenPR | September 29, 2020

Read More 'ZTS' Stories Here

ZTS Price Returns

1-mo 0.93%
3-mo 13.03%
6-mo 29.65%
1-year 34.44%
3-year 154.32%
5-year 296.52%
YTD 23.72%
2019 55.71%
2018 19.45%
2017 35.55%
2016 12.64%
2015 12.18%

ZTS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ZTS Dividend History

Continue Researching ZTS

Here are a few links from around the web to help you further your research on Zoetis Inc's stock as an investment opportunity:

Zoetis Inc (ZTS) Stock Price | Nasdaq
Zoetis Inc (ZTS) Stock Quote, History and News - Yahoo Finance
Zoetis Inc (ZTS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7357 seconds.